Amarantus Bioscience (OTC:AMBS) Stock, Quote.Headers.trade-ideas

Amarantus Bioscience Holdings Inc is a biopharmaceutical company. It is focused on developing therapeutic products for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company's prime therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia. The group's diagnostics division is dedicated to the development and commercialization of neurology diagnostic products. Its diagnostic product, LymPro Test is a blood-based assay to diagnose Alzheimer's disease.

Cannabis

News

Education

Markets

General

AMBS

BIOIF

CCHWF

CNBS

EMOR

GNLN

GWPH

HMLSF

IIPR

KSHB

MEDIF

PLPRF

PRGO

RKDA

THCX

TLLTF

VREOF

YOLO

TSX:WEED

CSE:DYME

TSX:LABS

CSE:PLUS

HARVF

CSE:BIO

CSE:TILT

The Week In Cannabis: Drake And Tony Hawk Get In The Weeds, Linton Joins Vireo, And A Myriad Of Earnings

Long Ideas

Short Ideas

Rumors

Small Cap

After-Hours Center

Movers

Trading Ideas

CADC

WNYN

Benzinga&#39;s Microcap Movers for Thursday November 1, 2012

Global

CNAM

Benzinga&#39;s Microcap Movers for Monday September 24, 2012 

AMARANTUS BIOSCIENCE HLDG by Amarantus Bioscience Holdings, Inc.

Amarantus Bioscience Holdings Inc

&nbsp;
&middot;Exclusive Distribution agreement covers North America, Latin America, SE Asia, Europe
&middot;Validation of Gnomegen qPCR kits now complete at CLIA/CAP-certified lab partner
&middot;Focus now on commercialization of combination PCR/antibody testing paradigm
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB:<a class="ticker" href="/stock/TOMDF#OTCQB">TOMDF</a>), a commercialin vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, as well as antibody and PCR tests for COVID-19, today announced that it has entered into an exclusive distribution agreement with Gnomegen LLC (&quot;Gnomegen&quot;) for the distribution of its digital and quantitative polymerase chain reaction (Digital PCR and qPCR) COVID-19 testing kits in North America, Europe, Southeast Asia and Latin America. In addition, the Company announced that Gnomegen&#39;s qPCR test received Emergency Use Authorization (&quot;EUA&quot;) from the US Food &amp; Drug Administration (FDA) diagnostic test for COVID-19 on May 8th, 2020. Further, the Company announced that it has completed validation testing for the Gnomegen qPCR reagents and is now entering preparations to commercially launch the test in the United States through its partner CLIA lab.
On April 15, 2020, CMS increased its payment rates for High-Throughput SARS-CoV-2 diagnostic tests that use high-throughput technologies allowing for increased capacity and faster results to&nbsp;$100&nbsp;per test. A High-Throughput testing lab can process at least 200 specimens per day using &quot;highly-sophisticated equipment that requires specially trained technicians and more more-intensive processes to assure quality,&quot; according to CMS. Todos expects that its CLIA lab partner will be able to process up to 2,000 tests per day with existing equipment, and can ramp up to 7,000 tests per day over the summer of 2020.
&quot;Todos Medical has been positioning itself as a distribution partner to testing labs throughout the world, including high-complexity CLIA labs here in the United States, by securing stable access to large quantities of high quality Digital PCR and qPCR reagents, RNA extraction reagents, RNA sample collection kits, automated RNA extraction machines and validated point-of-care fingerprick antibody tests that are currently authorized to be run in a high-complexity CLIA lab environments,&quot; said Gerald Commissiong, President &amp; CEO of Todos. &quot;We believe that in order to achieve the testing capacity required to address COVID-19, it is important for labs transitioning into COVID testing to have access to quality materials and supplies, and to be able to do both antibody testing and PCR testing. We will have access to potentially over 2 million extraction kits per week based on existing contracts with our existing suppliers, and now that we have an EUA-approved qPCR product we can begin to market a full solution to labs in the US and abroad so that they can meet the demands of the market as it matures heading into the summer of 2020.&quot;
About the SARS-CoV-2 Coronavirus (COVID-19)
Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is the disease caused by SARS-CoV-2.
About Todos Medical Ltd.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB:<a class="ticker" href="/stock/TOMDF#OTCQB">TOMDF</a>) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company&#39;s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer&#39;s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos&#39; two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista&#39;s proprietary commercial-stage Videssa&reg; breast cancer blood test. The transaction is expected to close in the&nbsp;second quarter&nbsp;of 2020.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC:<a class="ticker" href="/stock/AMBS#OTC">AMBS</a>), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer&#39;s disease. Todos expected to complete the remaining unowned interest in Breakthrough in the&nbsp;second quarter&nbsp;of 2020.
Todos recently entered into distribution agreements with China-based companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements covering the U.S. and Israel with Gibraltar Brothers &amp; Associates, LLC, a U.S.-based subsidiary of Shanghai Liangrun Biomedicine Technology Co. (Shanghai), for its proprietary colloidal gold immunochromatography (Colloidal Gold) point-of-care IgM/IgM-based antibody test kits, and with 3DMedicine Science &amp; Technology Co (3DMed), a China-based cancer precision medicine company, for distribution in the U.S. and Israel of its ANDiS&reg; SARS-CoV-2 Detection Kit (COVID), ANDiS&reg; SARS-CoV-2 &amp; Influenza A/B Detection Kit (COVID/Flu) and its proprietary ANDiS&reg;350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). Todos has formed Corona Diagnostics, LLC, a joint venture with Emerald Organic Products, Inc. (OTC:<a class="ticker" href="/stock/EMOR#OTC">EMOR</a>), to support the commercialization of its COVID-19 testing paradigm.
For more information, please visit&nbsp;<a href="https://www.todosmedical.com/">https://www.todosmedical.com/</a>
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Investor and Corporate Contact:
Kim Sutton Golodetz
LHA Investor Relations
Senior Vice President
(212) 838-3777
<a href="https://www.globenewswire.com/Tracker?data=mn8kqLq9cQl_GBCPBFiKCgo3aJcfs0dDafy5fuYSaoU1p1HC2rRwvGvkcQQsyK7f6hMDVWDShrvHuHy5X1lemRMDdrU9rPssS7cqiicJWdo=" target="_blank">kgolodetz@lhai.com</a>

&nbsp;
Corporate Contact:
Daniel Hirsch
Todos Medical
(347) 699-0029
<a href="mailto:Dan.h@todosmedical.com">Dan.h@todosmedical.com</a>
<img src="https://www.globenewswire.com/newsroom/ti?nf=NzkxODQxOSMzNTAzODc4IzUwMDA3MTA4NA==" style="height:1px; width:1px" />
<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/624cff64-b3a1-44e9-bdf2-86c5f618ad6c"><img alt="Primary Logo" src="https://ml.globenewswire.com/media/624cff64-b3a1-44e9-bdf2-86c5f618ad6c/small/5e70ba2109b32d0004a916bd-1-jpg.jpg" style="height:150px; width:106px" /></a>

Press Releases

TOMDF

Todos Medical Enters Into Direct Exclusive Distribution Agreement With Gnomegen and Announces US FDA Emergency Use Authorization for its COVID-19 qPCR Test Kits

Amarantus Reports Received Notice of Allowance from European Patent Office for MANF, CDNF in Treatment of Retinal Disorders

Earnings

Amarantus Bioscience Holdings Reports Q1 Loss $0.01 Vs Prios Loss $0.01

Amarantus BioScience Holdings (OTCQB: <a class="ticker" href="/stock/ambs#OTCQB">AMBS</a>) announced that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug status for MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of retinitis pigmentosa (RP). RP refers to a group of inherited diseases causing retinal degeneration often leading to blindness. The Company previously announced in December of 2014 that it also received orphan drug designation for MANF for the treatment of RP from the U.S. Food and Drug Administration (FDA).
	"We are extremely pleased to have received European orphan drug status for our promising investigational product, MANF in RP," said Gerald E. Commissiong, President &amp; CEO of Amarantus BioScience Holdings, Inc. "This EU orphan designation, combined with our recent U.S. orphan designation, positions MANF for an accelerated global regulatory product development pathway to address the significant unmet need in this important ophthalmologic indication."
	Orphan drug designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening
 <a href="http://www.benzinga.com/pressreleases/15/04/g5454858/amarantus-granted-european-union-orphan-drug-designation-for-manf-for-t">See full press release</a>

Amarantus Granted EU Orphan Drug Designation for MANF for Treatment of Retinitis Pigmentosa

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, announces that positive neuroprotective properties for the Company's MANF therapeutic were reported in a preclinical research study conducted by the Department of Orthopaedics at Qilu Hospital of Shandong University, in Jinan, China. Specifically, a published abstract of the study concluded, “These findings demonstrate that MANF shows the potential to alleviate cell damage and inflammation in rat primary astrocytes by suppressing ER (endoplasmic reticulum) stress, indicating that MANF plays an important role in astrocyte inflammation and functioning and may suggest a promising strategy for neuroprotection in the central nervous system.” 

“The findings from the study at Shandong University are consistent with the results we obtained in our own research with MANF on rat models for Parkinson's disease, which were reported in March 2013,” said John W. Commissiong, Ph.D., Chief Scientific Officer of Amarantus. “We are very pleased that independent research is contributing to the further understanding of MANF. The protective activity demonstrated by this independent work clearly suggests MANF may have utility in the treatment of conditions such as stroke, post-stroke recovery, Traumatic Brain Injury and concussion, as well as having relevance to the use of MANF in Parkinson's disease. We continue to conduct additional experiments with MANF in support of a planned Investigational New Drug (IND) application to the FDA.”

Amarantus Reports Positive Results on MANF Neuroprotective Properties Demonstrated in Preclinical Study in China 

Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:

Warp 9

Shares of Warp 9 (OTC: <a class="ticker" href="/stock/wnyn#OTC">WNYN</a>), the Santa Barbara, CA provider of e-commerce services for midsize online sellers, rose 500% Thursday on 17.5 million shares.

Warp 9 CFO Greg Boden told Benzinga there was no company news released to account for the move, but acknowledged that he did notice the stock was being promoted by a penny stock service. 

Boden said he gets about one call a week from interested buyers, but no deal has been made. He did say the company does have some things in the works, but nothing has been made public.

Warp 9 closed at $0.04 on Thursday.

Amarantus BioSciences

Amarantus BioSciences (OTC: <a class="ticker" href="/stock/ambs#OTC">AMBS</a>), the Sunnyvale, CA development-stage biotechnology company, rose 158% Thursday on 49 times average volume.

Amarantus BioSciences announced Thursday that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in 
disease states where no other treatment options are currently available.

Amarantus BioSciences closed at $0.02 on Thursday.

China Advanced Construction Materials Group

Shares of China Advanced Construction Materials Group (NASDAQ: <a class="ticker" href="/stock/cadc#NASDAQ">CADC</a>), the China-based producer of advanced, certified eco-friendly ready-mix concrete, rose 62.98% Thursday on 13.5 times average volume.

China Advanced Construction Materials Group shares rose following a strong China PMI report.

China Advanced Construction Materials Group closed at $0.70 on Thursday.

The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment.

Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.

Benzinga's Microcap Movers for Thursday November 1, 2012

Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:

Amarantus BioSciences

Shares of Amarantus BioSciences (OTC: <a class="ticker" href="/stock/ambs#OTC">AMBS</a>), the Sunnyvale, CA biotechnology company, rose 125% Monday on 8 million shares.

In an 8-K filing Friday, Amarantus stated: On August 23, 2012 we entered into a Convertible Promissory Note with PENSCO Trust Co. FBO Robert L. Harris. Mr. Harris is currently a member of our board of directors and has lent us the principal sum of $50,000 under the terms of the Note. The Note accrues interest at a rate of six percent per annum and is due and payable within 180 days unless extended by agreement of the parties. The Note may be prepaid without penalty.

The Note may be converted in whole or in part, at the election of the holder, into shares of our common stock at a price of $0.015 per share. The conversion price will be adjusted proportionately in the event of any split, reorganization, or reclassification of our common stock. In the event of our default, the Note will bear interest at the rate of twelve percent per annum.

Amarantus BioSciences closed at $0.0115 on Monday.

Longwei Petroleum

Shares of Longwei Petroleum (NYSE: <a class="ticker" href="/stock/lph#NYSE">LPH</a>), the China-based energy company, rose 21.49% Monday on almost 9 times average volume.

Longwei Petroleum announced Monday that it will complete the purchase of the assets of Huajie Petroleum by the end of this month.

Longwei will acquire the assets of Huajie for a total purchase price of approximately $110.6 million. The Company has agreed with the seller that the final payment of approximately $23.7 million will be paid on or before September 30, 2012. The Company currently has paid RMB 550 million (approximately US $86.9 million) on deposit for the purchase.

Longwei Petroleum closed at $1.47 on Monday.

China Armco Metals

China Armco Metals (NYSE: <a class="ticker" href="/stock/cnam#NYSE">CNAM</a>), the San Mateo, CA importer and distributor of metal ore and non-ferrous metals, rose 19.40% Monday on 19 times average volume.

China Armco Metals announced Monday that Armco Renewable Metals, the Company's wholly owned subsidiary, has delivered a new order for scrap steel to a client in China. The order calls for the delivery of total 30,000 metric tons of various scrap steels with an aggregate contract value of approximately of $11.7 million. The order was delivered by September 21, 2012.

China Armco Metals closed at $0.41 on Monday.

The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment.

Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.

Benzinga's Microcap Movers for Monday September 24, 2012 

Amarantus Bioscience

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Amarantus Bioscience

Amarantus Bioscience (AMBS) Forecast

Amarantus Bioscience (OTC:AMBS) Stock, Quote.Headers.trade-ideas